Federated Hermes’s Aimmune Therapeutics AIMT Stock Holding History

Federated Hermes’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-133,470	Closed	-$4.47M	–	2419
2019 Q4	$4.47M	Buy	+133,470	New	+$3.73M	0.01%	803
2018 Q4	–	Sell	-25,000	Closed	-$682K	–	2367
2018 Q3	$682K	Sell	25,000 -10,000	-29%	-$283K	﹤0.01%	1433
2018 Q2	$941K	Sell	35,000 -46,455	-57%	-$1.42M	﹤0.01%	1308
2018 Q1	$2.59M	Buy	81,455 +46,455	+133%	+$1.63M	0.01%	858
2017 Q4	$1.32M	Buy	35,000 +15,000	+75%	+$484K	﹤0.01%	1112
2017 Q3	$496K	Hold	20,000	–	–	﹤0.01%	1371
2017 Q2	$411K	Hold	20,000	–	–	﹤0.01%	1423
2017 Q1	$435K	Buy	+20,000	New	+$410K	﹤0.01%	1361
2016 Q2	–	Sell	-50,000	Closed	-$678K	–	2221
2016 Q1	$678K	Hold	50,000	–	–	﹤0.01%	1198
2015 Q4	$923K	Hold	50,000	–	–	﹤0.01%	1120
2015 Q3	$1.27M	Buy	+50,000	New	+$1.17M	﹤0.01%	1027

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Federated Hermes's AIMT Position: Q1 2020 in Review

Federated Hermes sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 133,470 shares — an estimated $4.47M sold.

Federated Hermes first reported a position in AIMT in Q3 2015 and held it in 11 quarters. The position peaked at $4.47M in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

Federated Hermes reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
Federated Hermes sold 133,470 Aimmune Therapeutics shares in Q1 2020, an estimated $4.47M.
Federated Hermes first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 11 quarters.
Federated Hermes's Aimmune Therapeutics position peaked at $4.47M in Q4 2019.
161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Federated Hermes's 13F filing for Q1 2020, filed 13 May 2020.